CytomX Therapeutics Inc (NASDAQ:CTMX) – Wedbush cut their Q1 2018 earnings estimates for shares of CytomX Therapeutics in a research report issued on Thursday. Wedbush analyst R. Driscoll now expects that the biotechnology company will post earnings per share of ($0.27) for the quarter, down from their previous forecast of ($0.22). Wedbush also issued estimates for CytomX Therapeutics’ Q2 2018 earnings at ($0.31) EPS, Q3 2018 earnings at ($0.34) EPS, Q4 2018 earnings at ($0.36) EPS, FY2018 earnings at ($1.28) EPS, FY2019 earnings at ($1.81) EPS, FY2020 earnings at ($3.73) EPS and FY2021 earnings at ($2.60) EPS.
Other equities research analysts also recently issued reports about the stock. BidaskClub upgraded shares of CytomX Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, December 15th. Zacks Investment Research downgraded shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday. Jefferies Group raised their target price on shares of CytomX Therapeutics to $40.00 and gave the company a “buy” rating in a research note on Thursday, March 8th. Cantor Fitzgerald set a $40.00 target price on shares of CytomX Therapeutics and gave the company a “buy” rating in a research note on Thursday, March 8th. Finally, ValuEngine downgraded shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Three analysts have rated the stock with a sell rating, two have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $35.67.
CytomX Therapeutics (NASDAQ CTMX) opened at $33.04 on Monday. CytomX Therapeutics has a 1-year low of $13.00 and a 1-year high of $35.00. The firm has a market capitalization of $1,280.00 and a PE ratio of -28.24.
In other CytomX Therapeutics news, insider Sean A. Mccarthy sold 13,052 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $21.04, for a total transaction of $274,614.08. Following the completion of the sale, the insider now directly owns 17,695 shares in the company, valued at $372,302.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Frederick W. Gluck sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 26th. The stock was sold at an average price of $22.29, for a total transaction of $111,450.00. The disclosure for this sale can be found here. Insiders sold a total of 132,626 shares of company stock valued at $3,709,830 over the last quarter. 8.00% of the stock is currently owned by company insiders.
Hedge funds have recently modified their holdings of the business. New York State Common Retirement Fund lifted its position in CytomX Therapeutics by 48.8% during the second quarter. New York State Common Retirement Fund now owns 31,100 shares of the biotechnology company’s stock worth $482,000 after acquiring an additional 10,199 shares during the last quarter. Trexquant Investment LP acquired a new stake in CytomX Therapeutics during the third quarter worth approximately $474,000. Hamilton Lane Advisors LLC lifted its position in CytomX Therapeutics by 77.8% during the fourth quarter. Hamilton Lane Advisors LLC now owns 50,394 shares of the biotechnology company’s stock worth $1,064,000 after acquiring an additional 22,048 shares during the last quarter. California State Teachers Retirement System lifted its position in CytomX Therapeutics by 27.8% during the second quarter. California State Teachers Retirement System now owns 51,430 shares of the biotechnology company’s stock worth $797,000 after acquiring an additional 11,200 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its position in CytomX Therapeutics by 47.3% during the third quarter. Wells Fargo & Company MN now owns 60,739 shares of the biotechnology company’s stock worth $1,104,000 after acquiring an additional 19,506 shares during the last quarter. Hedge funds and other institutional investors own 78.50% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/03/14/q1-2018-eps-estimates-for-cytomx-therapeutics-inc-reduced-by-analyst-ctmx.html.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.